It indicates that TRK inhibitor is more effective than anti-PD-1 inhibitor monotherapy for patients with NTRK fusion-positive NSCLC in spite of higher TMB and positive PD-L1 expression simultaneously. This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.